Success at multimodal, multi-indication, deep-pipelined Incyte—where commercial operations are as familiar as pre-discovery activity is—begins at the earliest opportunity to achieve research and discovery efficiencies. The company’s a bit larger than those we typically cover on the Business of Biotech, and that’s okay! Sometimes, the smartest approach to creating your own masterpiece is to study the masters On this episode of the podcast, we sit down with Incyte’s Group Vice President and head of its Inflammation and AutoImmunity Group, Jim Lee, M.D., Ph.D. for a dissection of the company’s approach to the comprehensive and efficient R&D that leads to repeated clinical and commercial success.  Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!